Clinical Trial

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-02.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07215650
Lead Sponsor Candid Therapeutics
Conditions Generalized Myasthenia Gravis
Enrollment 44 participants
Start Date 2025-09-16
Primary Completion 2027-12 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-17